SAN DIEGO, August 19, 2025 – Knobbe Martens partners Joe Reisman and Ryan Melnick serve as IP counsel to Ligand Pharmaceuticals Incorporated, a biopharmaceutical royalty aggregator. Dr. Reisman and Dr….

In the AdAge article “How Brands Can Avoid Risk When Bidding on Competitor Trademarks as Search Keywords,” lawyers Jonathan Menkes and Zachary Greenberg explore the complex legal landscape of digital…

IRVINE, Calif., August 14, 2025 – Knobbe Martens is pleased to share that a number of the firm’s partners have been recognized in the 2025 edition of the IAM Strategy…

IRVINE, Calif., August 14, 2025 – Knobbe Martens is pleased to share that partners Andrea Cheek, Kendall Loebbaka, and Adam Powell have been named to Benchmark Litigation’s 2025 “40 &…

Combination Dosing Regimen Not Obvious Despite Overlapping Prior-Art Ranges Justin J. Gillett & Alex Martin del Campo JANSSEN PHARMACEUTICALS, INC. v. TEVA PHARMACEUTICALS USA, INC. Before Prost, Reyna, and Taranto….

Space Technology Investments Clear the Launch Tower in 2025 Tom Cowan Investments in space technology are off to a strong start in the first half of 2025. The rising trend…

July Federal Circuit Newsletter (Japanese) July Federal Circuit Newsletter (Chinese)   Combination Dosing Regimen Not Obvious Despite Overlapping Prior-Art Ranges In Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., Appeal…

Speaking with Law360 for an article on career prospects and job satisfaction for recent law school graduates, associate Zach Rufa said he felt “incredibly lucky” to have begun his legal…

In the latest installment of their Law360 column on recent noteworthy Federal Circuit decisions, partners Sean Murray and Jeremiah Helm examined the outcome in Eye Therapies LLC v. Slayback Pharma…

New blog to provide perspectives and insights on the aerospace industry, ranging from IP issues to policy, innovation and investment trends IRVINE, Calif., July 29, 2025 – Knobbe Martens is…